Intrathecal activation of the complement system and disability in multiple sclerosis

Journal of the Neurological Sciences

Volumn 157, Issue 2, 1998, Pages 168-174

  Sellebjerg, Finn ^a,b   Jaliashvili, Irakli ^b   Christiansen, Michael ^b   Garred, Peter ^c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Sector Diagnostics Statens Serum I ^*  (Denmark)

^c Rigshospitalet   (Denmark)

Author keywords

Acute optic neuritis; Cerebrospinal fluid immunology; Complement immunology; Multiple sclerosis

Indexed keywords

COMPLEMENT; MYELIN BASIC PROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COMPLEMENT ACTIVATION; DEMYELINATION; FEMALE; HUMAN; IMMUNOPATHOGENESIS; MALE; MULTIPLE SCLEROSIS; OPTIC NERVE DISEASE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN DETERMINATION;

ACUTE DISEASE; ADOLESCENT; ADULT; COMPLEMENT ACTIVATION; DEMYELINATING DISEASES; DISABILITY EVALUATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; OPTIC NEURITIS;

EID: 0032493080     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(98)00086-0     Document Type: Article

References (37)

1. Bhakdi S., Hugo F., Tranum-Jensen J. Functions and relevance of the terminal complement sequence. Blut. 60:1990;309-318.
2. Compston D.A.S., Morgan B.P., Campbell A.K., Wilkins P., Cole G., Thomas N.D.et al. Immunocytochemical localization of the terminal complement complex in multiple sclerosis. Neuropathol Appl Neurobiol. 15:1989;307-316.
3. Dalakas M.C., Illa I., Dambrosia J.M., Soueidan S.A., Stein D.P., Otero C.et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 329:1993;1993-2000.
4. Ebers G.C. Optic neuritis and multiple sclerosis. Arch Neurol. 42:1985;702-704.
5. Fazekas F., Deisenhammer F., Strasser-Fuchs S., Nahler G., Mamoli B. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in multiple sclerosis. Lancet. 349:1997;589-593.
6. Felgenhauer K. Protein size and cerebrospinal fluid composition. Klin Wochenschr. 52:1974;1158-1164.
7. Frank M.M., Basta M., Fries L.F. The effects of intravenous immune globulin on complement-dependent immune damage of cells and tissues. Clin Immunol Immunopathol. 62:1992;S82-S86.
8. Frederiksen J.L., Larsson H.B., Olesen J., Stigsby B. MRI, VEP, SEP and biothesiometry suggest monosymptomatic acute optic neuritis to be a first manifestation of multiple sclerosis. Acta Neurol Scand. 83:1991;343-350.
9. Garred P., Mollnes T.E., Lea T. Quantification in enzyme-linked immunosorbent assay of a C3 neoepitope expressed on activated human complement factor C3. Scand J Immunol. 27:1988;329-335.
10. Garred P., Mollnes T.E., Lea T., Fischer E. Characterization of a monoclonal antibody MoAb bH6 reacting with a neoepitope of human C3 expressed on C3b, iC3b, and C3c. Scand J Immunol. 27:1988;319-327.
11. Gay D., Esiri M. Blood-brain barrier damage in acute multiple sclerosis plaques. Brain. 114:1991;557-572.
12. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661.
13. Jacobs L.D., Cookfair D.L., Rudick R.A., Herndon R.M., Richert J.R., Salazar A.M.et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol. 39:1996;285-294.
14. Johnson K.P., Brooks B.R., Cohen J.A., Ford C.C., Goldstein J., Lisak R.P.et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology. 45:1995;1268-1276.
15. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology. 33:1983;1444-1452.
16. Lublin F.D., Reingold S.C. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology. 46:1996;907-911.
17. Mollnes T.E., Høgåsen K., Hoaas B.F., Michaelsen T.E., Garred P., Harboe P.et al. Inhibition of complement-mediated red cell lysis by immunoglobulins is dependent on the Ig isotype and its C1 binding properties. Scand J Immunol. 41:1995;449-456.
18. Mollnes T.E., Lea T., Harboe M. Detection and quantification of the terminal C5b-9 complex of human complement by a sensitive enzyme-linked immunosorbent assay. Scand J Immunol. 22:1985;197-202.
19. Mollnes T.E., Lea T., Harboe M., Tschopp J. Monoclonal antibodies recognizing a neoantigen of poly(C9) detect the human terminal complement complex in tissue and plasma. Scand J Immunol. 22:1985;183-195.
20. Mollnes T.E., Vandvik B., Lea T., Vartdal F. Intrathecal complement activation in neurological diseases evaluated by analysis of the terminal complement complex. J Neurol Sci. 78:1987;17-28.
21. Morgan BP. Complement. Clinical aspects and relevance to disease. London: Academic Press, 1990:1-215.
22. Morgan B.P., Campbell A.K., Compston D.A. Terminal component of complement (C9) in cerebrospinal fluid of patients with multiple sclerosis. Lancet. 2:1984;251-254.
23. Morgan B.P., Gasque P. Expression of complement in the brain: role in health and disease. Immunol Today. 17:1997;461-466.
24. Morgan B.P., Gasque P., Singhrao S.K., Piddlesden S.J. Role of complement in inflammation and injury in the nervous system. Exp Clin Immunogenet. 14:1997;19-23.
25. Murphy B.F., Kirszbaum L., Walker I.D., d'Apice A.J. SP-40,40, a newly identified normal human serum protein found in the SC5b-9 complex of complement and in the immune deposits in glomerulonephritis. J Clin Invest. 81:1988;1858-1864.
26. Perkin GD, Rose FC. Optic neuritis and its differential diagnosis. Oxford: Oxford University Press, 1979:1-292.
27. Piddlesden S.J., Lassmann H., Zimprich F., Morgan B.P., Linington C. The demyelinating potential of antibodies to myelin oligodendrocyte glycoprotein is related to their ability to fix complement. Am J Pathol. 143:1993;555-564.
28. Piddlesden S.J., Storch M.K., Hibbs M., Freeman A.M., Lassmann H., Morgan B.P. Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody-mediated demyelinating experimental allergic encephalomyelitis. J Immunol. 152:1994;5477-5484.
29. Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C.et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 13:1983;227-231.
30. Rieckmann P., Altenhofen B., Riegel A., Baudewig J., Felgenhauer K. Soluble adhesion molecules (sVCAM-1 and sICAM-1) in cerebrospinal fluid and serum correlate with MRI activity in multiple sclerosis. Ann Neurol. 41:1997;326-333.
31. Sanders M.E., Koski C.L., Robbins D., Shin M.L., Frank M.M., Joiner K.A. Activated terminal complement in cerebrospinal fluid in Guillain-Barre syndrome and multiple sclerosis. J Immunol. 136:1986;4456-4459.
32. Scolding N.J., Morgan B.P., Houston W.A., Linington C., Campbell A.K., Compston D.A. Vesicular removal by oligodendrocytes of membrane attack complexes formed by activated complement. Nature. 339:1989;620-622.
33. Sellebjerg F., Christiansen M. Qualitative assessment of intrathecal IgG synthesis by isoelectric focusing and immunodetection: interlaboratory reproducibility and interobserver agreement. Scand J Clin Lab Invest. 56:1996;135-143.
34. Shirazi Y., Imagawa D.K., Shin M.L. Release of leukotriene B4 from sublethally injured oligodendrocytes by terminal complement complexes. J Neurochem. 48:1987;271-278.
35. Steinman L. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell. 85:1996;299-302.
36. Wu E., Brosnan C.F., Raine C.S. SP-40,40 immunoreactivity in inflammatory CNS lesions displaying astrocyte/oligodendrocyte interactions. J Neuropathol Exp Neurol. 52:1993;129-134.
37. van Engelen B.G.M., Lamers K.J.B., Gabreels F.J.M., Wevers R.A., van Geel W.J.A., Borm G.F. Age-related changes of neuron-specific enolase, S-100 protein, and myelin basic protein concentrations in cerebrospinal fluid. Clin Chem. 38:1992;813-816.